sibutramine

(redirected from Sibutramine hydrochloride)
Also found in: Dictionary.
Related to Sibutramine hydrochloride: Reductil

sibutramine

 [si-bu´trah-mēn″]
an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally.

sibutramine

/si·bu·tra·mine/ (si-bu´trah-mēn″) an anorectic used as the hydrochloride salt in the management of obesity.

sibutramine

(sə-byo͞o′trə-mĭn, -mēn′)
n.
A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes.

sibutramine

an appetite suppressant.
indications It is used to treat obesity in conjunction with other treatments.
contraindications The following factors prohibit its use: known hypersensitivity to this drug, hypothyroidism, anorexia nervosa, severe hepatic/renal disease, uncontrolled hypertension, cerebrovascular accident, history of coronary artery disease, congestive heart failure, arrhythmias, pregnancy, and lactation.
adverse effects Tachycardia is a life-threatening effect of this drug. Other adverse effects include headache, insomnia, seizures, stimulation, drowsiness, dizziness, nervousness, emotional lability, hypotension, palpitations, vasodilation, anorexia, constipation, dry mouth, taste aberration, nausea, increased appetite, dysmenorrhea, laryngitis, pharyngitis, rhinitis, sinusitis, rash, and sweating.

sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

 
Indications
Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).

Adverse effects
Headache, dry mouth, anorexia, constipation.

Contraindications
Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.

sibutramine

Meridia® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity.

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.

sibutramine

An antiobesity drug that acts on the nervous system in a manner similar to that of Prozac so that the patient is able to feel satisfied with smaller amounts of food. The drug is not recommended for people under 18 and is used for a maximum period of one year. It is prescribed mainly for those with a body mass index (BMI) of 30 or over. Brand name Reductil.

Sibutramine

An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.
Mentioned in: Weight Loss Drugs

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.

sibutramine (sībū´trəmēn),

n an FDA-approved prescription drug for weight loss containing a combination of serotonin and andronergics that has been shown to promote a feeling of fullness while apparently not influencing hunger; Meridia is an example.
References in periodicals archive ?
Investigators for the MHRA visiting the company had discovered Sildenafil and Tadalafil, both used to treat erectile dysfunction, Carisoprodol, used as a muscle relaxant, and Sibutramine Hydrochloride, used to treat obesity, the agency said.
Among these products are the two most widely prescribed anti obesity drugs orlistat (Xenical-Roche) and sibutramine hydrochloride (Meridia-Abbott Laboratories).
Sibutramine hydrochloride monohydrate (marketed under the trade name MERIDIA in the U.